Mode
Text Size
Log in / Sign up

HIV infection is associated with significantly higher myocardial fibrosis markers in patients living with HIVHIV infection is linked to increased heart muscle scarring

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that HIV infection is associated with significantly higher markers of myocardial fibrosis, including LGE and T1 values.

This meta-analysis of 13 studies evaluates cardiac magnetic resonance (CMR) parameters in patients living with HIV (PLWH) compared to healthy controls. The primary finding is a significant increase in late gadolinium enhancement (LGE) in PLWH (OR: 5.47; 95% CI: 1.90-15.64, p<0.001), which serves as a marker for myocardial fibrosis. Additionally, PLWH showed significantly higher T1 values (mean difference: 13.78 ms; 95% CI: 9.16-18.40, p<0.001) and extracellular volume (ECV) (mean difference: 1.46; 95% CI: 0.21-2.71, p=0.02).

Other markers, including T2 values, left ventricular ejection fraction (LVEF), and pro B-type natriuretic peptide (BNP), did not show significant differences between the groups. The analysis also identified correlations between ECV and factors such as white race, Hepatitis C, and smoking.

Clinically, these findings suggest that HIV is associated with a significantly elevated rate of myocardial fibrosis. However, the study notes that the results represent an association rather than a direct cause. The evidence is based on a meta-analysis of 13 studies, and the clinical implications for specific treatment changes are not detailed.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the specific cardiac impacts of HIV. It confirms that HIV is associated with significantly higher myocardial fibrosis markers, specifically LGE (OR: 5.47) and T1 values. This finding adds to the broader understanding of myocardial fibrosis mechanisms, such as the roles of programmed cell death and the TWEAK-Fn14 axis mentioned in prior coverage.

Living with HIV can impact more than just the immune system; it can also affect the heart. Researchers looked at data from over 1,400 people living with HIV and compared them to a group of healthy individuals to see how the virus affects heart tissue.

The study found that people with HIV had significantly higher levels of myocardial fibrosis. This is a medical term for scarring in the heart muscle. They also found higher T1 values and higher extracellular volume, which are markers that suggest the heart tissue is changing due to the infection. These findings show a clear link between HIV and physical changes in the heart.

While the study shows a strong connection between HIV and heart scarring, it is important to remember that these results show an association, not a direct cause. The data also showed that certain factors like smoking and having Hepatitis C can also influence these heart markers. If you have concerns about your heart health while managing HIV, talk to your doctor about what these findings mean for your specific care.

What this means for you:
People living with HIV show significantly higher levels of heart muscle scarring than healthy individuals.

Common questions

What does heart scarring mean for people with HIV?

The study found that people living with HIV have significantly higher levels of myocardial fibrosis, which is scarring of the heart muscle. This was confirmed by looking at markers like T1 values and extracellular volume. These findings show that the virus is linked to physical changes in heart tissue.

Are there other factors that affect heart health in this study?

Yes, the study found that other factors can also influence heart tissue markers. Specifically, there were correlations between heart markers and smoking, as well as the presence of Hepatitis C. These factors can contribute to the overall health of the heart muscle.

Did the study find any differences in heart pumping strength?

The study looked at the Left Ventricular Ejection Fraction, which measures how well the heart pumps blood. However, the results showed no significant differences in this specific measurement between people living with HIV and the healthy control group.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
HIV infection significantly elevated the odds of cardiovascular diseases, including myocardial fibrosis. We aimed to determine the difference of late gadolinium enhancement (LGE), extracellular volume (ECV), T1, and T2 using cardiac magnetic resonance imaging (CMR) in patients living with HIV (PLWH) and healthy controls. The databases Scopus, Web of Science, Embase, and PubMed were searched systematically using relevant keywords. STATA version 17 was used for meta-analysis using random effect and fixed effect models for heterogeneous and non-heterogeneous analyses. An overall number of 13 studies were included in the current analysis involving 1425 PLWH and 766 healthy controls. PLWH showed significantly higher LGE (OR: 5.47, 95% CI: 1.90-15.64, p<0.001) and ECV (mean difference: 1.46, 95% CI: 0.21-2.71, p=0.02) compared to controls. However, differences in Left Ventricular Ejection Fraction (LVEF) were not significant (mean difference: -1.41, 95% CI: -2.81- -0.01, p=0.05). There were no meaningful disparities in pro B-type natriuretic peptide (BNP) values (mean difference: 8.67, 95% CI: 0.04-17.29, p=0.05) or T2 values (mean difference: 0.91 ms, 95% CI: -1.04-2.86, p=0.36), but T1 values were significantly higher in PLWH (mean difference: 13.78 ms, 95% CI: 9.16-18.40, p<0.001). In meta regression, LGE was correlated with nadir CD4 (z=-3.41, p-value<0.001). In addition, ECV was correlated with white race (Z=-3.97, p-value<0.001), Hepatitis C (Z=-2.08, p-value=0.037), and smoking (Z=2.05, p-value=0.041). HIV is related to a significantly elevated rate of myocardial fibrosis, and factors such as lower nadir CD4, white race, hepatitis C, and smoking were correlated with hepatitis C. Keywords: Myocardial fibrosis, HIV, AIDS, Cardiovascular diseases, Heart failure
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.